StockMarketWire.com - Caner and inflammatory diseases focused Tiziana Life Sciences said it planned to demerge its StemPrintER genomics-based personalised medicine business into a separate company.

The company said recent positive trial results on the prediction of disease recurrence in breast cancer patients backed the viability of StemPrintER as having the potential to be a standalone business.

On its own, StemPrintER could secure separate financial resources and sharpen its focus onto the personalised medicine market.

The separation would be done via a capital reduction and was subject to shareholder approval.


At 9:11am: [LON:TILS] Tiziana Life Sciences Plc share price was +8p at 93p



Story provided by StockMarketWire.com